PropertyValue
?:abstract
  • The ongoing coronavirus disease 19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become fatal for the world with affected population crossing over 25 million in more than 217 countries, consequently declared a global pandemic by the World Health Organization. Unfortunately, neither specific prophylactic or therapeutic drugs nor vaccines are available. To address the unmet medical needs, we explored a strategy identifying new compounds targeting the main protease (M(pro)) of SARS-CoV-2. Targeting the SARS-CoV-2 M(pro) crystal structure (PDB ID: 6LU7) a combination of in silico screening, molecular docking, and dynamic approaches, a set of 5000 compounds of the ZINC database were screened. As a result, we identified and ranked the top 20 compounds based on the scores of ligand-interaction, their drug-likeness properties, and their predicted antiviral efficacies. The prominent drug-like and potent inhibitory compounds are 2-[2-(2-aminoacetyl) aminoacetyl] amino-3-(4-hydroxyphenyl)-propanamide (ZINC000004762511), 6′-fluoroaristeromycin (ZINC000001483267) and cyclo (L-histidyl-L-histidyl) (ZINC000005116916) scaffolds. Further in vitro and in vivo validations are required to demonstrate anti-SARS-CoV-2 activities. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13337-020-00627-6) contains supplementary material, which is available to authorized users.
is ?:annotates of
?:creator
?:doi
  • 10.1007/s13337-020-00627-6
?:doi
?:journal
  • Virusdisease
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/8c0750d1aca332413d4a9887702aa920ad7a8471.json
?:pmcid
?:pmid
?:pmid
  • 33200084.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Structure-guided discovery approach identifies potential lead compounds targeting M(pro) of SARS-CoV-2
?:type
?:year
  • 2020-11-11

Metadata

Anon_0  
expand all